Adaptimmune Therapeutics PLC
ADAP0.055USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
87.31MMarket Cap
LossP/E TTM
More Details of Adaptimmune Therapeutics PLC Company
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC Info
Ticker SymbolADAP
Company nameAdaptimmune Therapeutics PLC
IPO dateMay 06, 2015
CEORawcliffe (Adrian George)
Number of employees506
Security typeDepository Receipt
Fiscal year-endMay 06
Address60 Jubilee Avenue
CityABINGDON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeOX14 4RX
Phone441235430000
Websitehttps://www.adaptimmune.com/
Ticker SymbolADAP
IPO dateMay 06, 2015
CEORawcliffe (Adrian George)
Company Executives of Adaptimmune Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+401293.00%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+401293.00%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Feb 4
Updated: Wed, Feb 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
7.01%
Renaissance Technologies LLC
1.53%
Morgan Stanley & Co. LLC
1.38%
Jane Street Capital, L.L.C.
1.06%
Acadian Asset Management LLC
0.56%
Other
88.47%
Shareholders
Shareholders
Proportion
Long Focus Capital Management LLC
7.01%
Renaissance Technologies LLC
1.53%
Morgan Stanley & Co. LLC
1.38%
Jane Street Capital, L.L.C.
1.06%
Acadian Asset Management LLC
0.56%
Other
88.47%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.54%
Research Firm
2.99%
Investment Advisor/Hedge Fund
0.84%
Investment Advisor
0.81%
Individual Investor
0.63%
Pension Fund
0.05%
Venture Capital
0.04%
Other
86.10%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
165
42.25M
57.79%
-8.12K
2025Q3
183
42.26M
58.51%
-57.25M
2025Q2
189
116.07M
65.05%
-1.37M
2025Q1
186
117.46M
62.78%
-44.42M
2024Q4
186
127.90M
58.86%
-11.67M
2024Q3
189
154.60M
64.35%
-2.20M
2024Q2
192
156.54M
67.34%
-7.97M
2024Q1
203
164.83M
67.18%
-6.80M
2023Q4
199
145.59M
71.95%
-5.54M
2023Q3
217
150.77M
70.44%
+3.59M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Long Focus Capital Management LLC
18.58M
7.01%
-5.18M
-21.80%
Sep 30, 2025
Renaissance Technologies LLC
4.05M
1.53%
+2.17M
+115.32%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.65M
1.38%
-568.56K
-13.48%
Sep 30, 2025
Jane Street Capital, L.L.C.
2.81M
1.06%
+2.81M
--
Sep 30, 2025
Acadian Asset Management LLC
1.49M
0.56%
-478.99K
-24.39%
Sep 30, 2025
BofA Global Research (US)
1.32M
0.5%
+177.96K
+15.59%
Sep 30, 2025
Alpha Architect, LLC
800.00K
0.3%
--
--
Sep 30, 2025
Menzel (Garry E)
611.22K
0.23%
+401.29K
+191.15%
Apr 11, 2025
B. Riley Wealth Advisors, Inc.
500.00K
0.19%
+500.00K
--
Sep 30, 2025
Rathbones Investment Management Limited
432.82K
0.16%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
